Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06529016 · ClinicalTrials.gov registry record · NA
Using Dichoptic Therapy to Treat Intermittent Exotropia
A NA study of Exotropia Intermittent, sponsored by Virginia Commonwealth University.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06529016 is a NA study of Exotropia Intermittent that is actively recruiting participants, run by Virginia Commonwealth University. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06529016, a NA study of Exotropia Intermittent, is actively recruiting participants, sponsored by Virginia Commonwealth University.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Intermittent exotropia is difficult to treat. The mainstay of treatment involves surgery, and in one long-term study authors found that as many as 60% of IXT required at least one re-operation.Patching of the non-dominant eye has also been tested in a large, multi-center randomized control trial and was not found to have a large benefit. More non-surgical treatment modalities are critical to improve the care in this condition.
Conditions Studied
Interventions
- DEVICE Luminopia, a virtual reality headset
- OTHER Paper pre- survey
- OTHER Paper Survey
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-07-26 |
| Est. Completion | 2026-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06529016
The ClinicalTrials.gov registry entry for NCT06529016 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Exotropia Intermittent appearing as the primary indexed condition, and to 3 interventions - of which Luminopia, a virtual reality headset is the first listed.
NCT06529016 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT06529016 about?
NCT06529016 is a clinical study titled "Using Dichoptic Therapy to Treat Intermittent Exotropia". Intermittent exotropia is difficult to treat. The mainstay of treatment involves surgery, and in one long-term study authors found that as many as 60% of IXT required at least one re-operation.Patching of the non-dominant eye has also been tested in a large, multi-center randomized control trial and...
What is the current status of trial NCT06529016?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2024-07-26. Estimated completion is 2026-06.
What conditions does trial NCT06529016 study?
This clinical trial studies the following conditions: Exotropia Intermittent.
What interventions are being tested in trial NCT06529016?
The interventions under investigation include: Luminopia, a virtual reality headset (DEVICE), Paper pre- survey (OTHER), Paper Survey (OTHER).
Who is sponsoring clinical trial NCT06529016?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06529016 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.